Today, Novo Nordisk A/S ( NVO ) has launched a pill version of Wegovy in the U.S., the news that many investors were waiting for. They’re now offering a 30-day supply at just $149 forI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind ...

Core Insights - GH Research (GHRS) focuses on proprietary mebufotenin-based therapies for depression, with its lead candidate being GH001, an inhaled formulation for treatment-resistant depression [1] Company Overview - GH Research is dedicated to developing innovative therapies for depression, particularly targeting treatment-resistant cases [1] - The company’s pipeline is centered around mebufotenin, indicating a specialized approach to addressing mental health challenges [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The analyst has been active in the investment space for five years, with a focus on identifying promising biotechnology companies and evaluating their scientific and financial fundamentals [1] Investment Focus - The analysis emphasizes the importance of understanding the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities [1] - The goal is to provide insights that help investors navigate the biotech sector, which is characterized by both significant opportunities and inherent risks [1]

Cybin Inc. ( CYBN ) stock is one that has failed to kick on in 2025, despite having a couple late stage assets in CYB003 and CYB004. And whilst over the past month shares have seenI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind dru ...

分组1 - Vanda Pharmaceuticals Inc. (VNDA) experienced a significant increase in stock price following the FDA's approval of Nereus for treating motion sickness [1] - The company is focused on developing innovative therapies, leveraging unique mechanisms of action and first-in-class treatments [1] - The analyst emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, and clinical trial design while balancing financial fundamentals [1] 分组2 - The biotech sector is characterized by the potential for breakthrough science to yield substantial returns, necessitating careful scrutiny of investment opportunities [1] - The analyst aims to provide insights that help investors understand both the opportunities and risks inherent in the biotech industry [1]

Core Insights - Outlook Therapeutics (OTLK) has faced significant challenges in 2025, particularly in gaining FDA approval for its drug Lytenava, despite its approval in the UK and EU [1] Company Overview - Outlook Therapeutics has struggled to align with FDA requirements, impacting its market performance and growth potential [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The focus is on identifying innovative biotechnology companies that offer unique therapeutic solutions and have the potential to reshape treatment paradigms [1] Investment Approach - The investment strategy emphasizes evaluating the scientific basis of drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]

Key Takeaways MLYS' lorundrostat hit key endpoints, supporting plans for an NDA submission in early 2026.LYEL rose as ronde-cel advanced in pivotal studies and new CAR T assets strengthened its oncology pipeline.INSM climbs on Brinsupri's FDA approval, despite a setback in a mid-stage rhinosinusitis study.The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector picked up in the past couple of months. This can be attributed to improved policies f ...

Core Insights - Lyell Immunopharma (LYEL) stock has experienced a significant increase of 191% year to date, indicating strong bullish momentum as it approaches 2026 [1] Company Overview - The company is focused on biotechnology, particularly in drug development, leveraging unique mechanisms of action and first-in-class therapies [1] - Lyell Immunopharma aims to reshape treatment paradigms through innovative platform technologies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis [1] - The analyst has been active in the investing space for five years, with a focus on biotech equity analysis for the last four years [1] Research Focus - The research emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Guangzhou Novaken Pharm Co., Ltd. 廣州新濟醫藥股份有限公司 (the "Company") (A joint stock company established in the People's R ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over up to one year Initiation of RECOVER-2 registrational trial planned in H1 2026, subject to sufficient financing CUPERTI ...

Core Insights - ABIVAX (ABVX) has been recognized as the best performing biotech stock in 2025, achieving a remarkable 1,470% increase year to date [1] Company Overview - The company focuses on innovative biotechnology solutions, emphasizing unique mechanisms of action and first-in-class therapies [1] - ABIVAX is positioned within a sector where breakthrough science can lead to significant financial returns, highlighting the importance of thorough analysis [1] Analyst's Perspective - The analysis combines scientific expertise with financial and market evaluation to provide insights into the biotech sector [1] - The approach includes assessing the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]